Randomized clinical trials: what gets published, and when?
作者信息
Hirsch Laurence
机构信息
Medical Communications at Merck Research Laboratories, Rahway, NJ 07065-0900, USA.
出版信息
CMAJ. 2004 Feb 17;170(4):481-3.
Abstract
摘要
相似文献
1
Randomized clinical trials: what gets published, and when?
CMAJ. 2004 Feb 17;170(4):481-3.
2
Full disclosure in industry-sponsored laboratory medicine research studies: statement by the Consortium of Laboratory Medicine Journal Editors.
Clin Chem. 2011 Mar;57(3):359-60. doi: 10.1373/clinchem.2010.160721. Epub 2010 Dec 20.
3
Media portrayal of conflicts of interest in herbal remedy clinical trials.
Health Law Rev. 2006;15(1):9-11.
4
5
Conflict of interest and cost-effectiveness analysis.
JAMA. 1999 Oct 20;282(15):1474-5. doi: 10.1001/jama.282.15.1474.
6
Understanding placebo effects in homeopathic clinical trials.
J Altern Complement Med. 2005 Oct;11(5):784. doi: 10.1089/acm.2005.11.784.
7
Tough-talking journal editor faces accusations of leniency.
N Y Times Web. 2006 Aug 1:F1, F3.
8
Addressing Bias and Conflict of Interest Among Biomedical Researchers.
JAMA. 2017 May 2;317(17):1723-1724. doi: 10.1001/jama.2017.3854.
9
New author guidelines - clinical trials and conflict of interest.
Vet Dermatol. 2008 Apr;19(2):51. doi: 10.1111/j.1365-3164.2008.00657.x.
10
Our conflicted medical journals.
N Y Times Web. 2006 Jul 23:WK11.
引用本文的文献
1
Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals.
Neth Heart J. 2012 Jun;20(6):279-87. doi: 10.1007/s12471-012-0277-7.
2
Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature.
Can J Surg. 2011 Oct;54(5):321-6. doi: 10.1503/cjs.008610.
3
Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals.
Mayo Clin Proc. 2009 Sep;84(9):811-21. doi: 10.4065/84.9.811.
4
SSRI treatment for under-18s.
CMAJ. 2004 Jun 8;170(12):1771; author reply 1171-2. doi: 10.1503/cmaj.1040396.
本文引用的文献
1
2
Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.
Am J Med. 2003 Oct 15;115(6):467-72. doi: 10.1016/s0002-9343(03)00422-4.
3
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?
JAMA. 2003 Aug 20;290(7):921-8. doi: 10.1001/jama.290.7.921.
4
Registering clinical trials.
JAMA. 2003 Jul 23;290(4):516-23. doi: 10.1001/jama.290.4.516.
5
Factors associated with failure to publish large randomized trials presented at an oncology meeting.
JAMA. 2003 Jul 23;290(4):495-501. doi: 10.1001/jama.290.4.495.
6
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ. 2003 May 31;326(7400):1167-70. doi: 10.1136/bmj.326.7400.1167.
7
Too much medicine? Or too little?
Bone. 2003 Apr;32(4):327-31. doi: 10.1016/s8756-3282(03)00022-x.
8
Comparison of caspofungin and amphotericin B for invasive candidiasis.
N Engl J Med. 2002 Dec 19;347(25):2020-9. doi: 10.1056/NEJMoa021585.
9
Conflicts of interest in drug development: the practices of Merck & Co., Inc.
Sci Eng Ethics. 2002 Jul;8(3):429-42. doi: 10.1007/s11948-002-0065-7.
10
Funding source, trial outcome and reporting quality: are they related? Results of a pilot study.
BMC Health Serv Res. 2002 Sep 4;2(1):18. doi: 10.1186/1472-6963-2-18.
Zotero 插件